A lack of close binaries among hot horizontal branch stars in globular clusters. II. NGC\,2808

Models based on their binary origin have been very successful in reproducing the properties of field subdwarf-B stars, but the observations of their analogues in globular clusters has posed new problems, while the discovery of multiple populations offered an appealing alternative scenario for the formation of these stars. We search for binaries of period P<200 days among a sample of blue horizontal branch stars (Teff=12000-22000 K) in NGC2808, a cluster known to host three distinct stellar populations and a multimodal horizontal branch. The final sample consists of 64 targets. The radial velocity of the targets was measured in fourteen epochs, spanning a temporal interval of about 75 days. We detect no RV variable object among stars cooler than the photometric G1 gap at 17000 K, while two close (P<10 days) and two intermediate-period (P=10-50 days) systems are found among hotter targets. The close and intermediate-period binary fraction for stars cooler than the gap are fc<5% and fip<10%, respectively, with 95% confidence. The most probable values among hotter stars are fc~20% and fip~30%, but the 90%- confidence level intervals are large (6-42% and 11-72%, respectively). The G1 gap appears as a discontinuity in the binary faction, with a higher incidence of binaries among hotter stars, but a constant increase in f with temperature rather than a discontinuity cannot be excluded from our observations. We find that intermediate-period binaries, never investigated before among cluster HB stars, could play an important role, being more than ~15-20% of the hottest stars of our sample. Our results indicate that fc among hot HB stars is most probably higher for younger clusters, confirming the recently proposed age-fc relation. However, the large observed difference in binary fraction between clusters (e.g. NGC2808 and NGC6752) is still not reproduced by binary population synthesis models

Is a binary fraction-age relation responsible for the lack of EHB binaries in globular clusters?

The recently-discovered lack of close binaries, among extreme horizontal branch (EHB) stars in Galactic globular clusters, has thus far constituted a major puzzle, in view of the fact that blue subdwarf stars - the field counterparts of cluster EHB stars - are well-known to present a high binary fraction. In this Letter, we provide new results that confirm the lack of close EHB binaries in globular clusters, and present a first scenario to explain the difference between field and cluster EHB stars. First, in order to confirm that the lack of EHB binaries in globular clusters is a statistically robust result, we undertook a new analysis of 145 horizontal branch stars in NGC6752, out of which forty-one belong to the EHB. To search for radial-velocity variations as a function of time, we repeated high-resolution (R=18500) spectroscopy of all stars, four times during a single night of observations. We detected a single, hot (25000 K), radial-velocity variable star as a close-binary candidate. From these results, we estimate an upper-limit for the close (period P < 5 day) binary fraction f among NGC6752 EHB stars of 16% (95% confidence level), with the most probable value being f=4%. Thus our results clearly confirm the lack of close binaries among the hot HB stars in this cluster. We suggest that the confirmed discrepancy between the binary fractions for field and cluster EHB stars is the consequence of an f-age relation, with close binaries being more likely in the case of younger systems. We analyze theoretical and observational results available in the literature, which support this scenario. If so, an age difference between the EHB progenitors in the field and in clusters, the former being younger (on average) by up to several Gyr, would naturally account for the startling differences in binary fraction between the two populations.Comment: Accepted for publication in A&A Lettersto the Edito

Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells

Peer reviewe

Loss-of-function mutation in IKZF2 leads to immunodeficiency with dysregulated germinal center reactions and reduction of MAIT cells

Peer reviewe

Novel Biochemical Markers of Psychosocial Stress in Women

Background: Prolonged psychosocial stress is a condition assessed through self-reports. Here we aimed to identify biochemical markers for screening and early intervention in women

Smoke, curtains and mirrors: the production of race through time and title registration

This article analyses the temporal effects of title registration and their relationship to race. It traces the move away from the retrospection of pre-registry common law conveyancing and toward the dynamic, future-oriented Torrens title registration system. The Torrens system, developed in early colonial Australia, enabled the production of ‘clean’, fresh titles that were independent of their predecessors. Through a process praised by legal commentators for ‘curing’ titles of their pasts, this system produces indefeasible titles behind its distinctive ‘curtain’ and ‘mirror’, which function similarly to magicians’ smoke and mirrors by blocking particular realities from view. In the case of title registries, those realities are particular histories of and relationships with land, which will not be protected by property law and are thus made precarious. Building on interdisciplinary work which theorises time as a social tool, I argue that Torrens title registration produces a temporal order which enables land market coordination by rendering some relationships with land temporary and making others indefeasible. This ordering of relationships with land in turn has consequences for the human subjects who have those relationships, cutting futures short for some and guaranteeing permanence to others. Engaging with Renisa Mawani and other critical race theorists, I argue that the categories produced by Torrens title registration systems materialise as race

Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes

BACKGROUND: Data are lacking on the long-term effect on cardiovascular events of adding sitagliptin, a dipeptidyl peptidase 4 inhibitor, to usual care in patients with type 2 diabetes and cardiovascular disease. METHODS: In this randomized, double-blind study, we assigned 14,671 patients to add either sitagliptin or placebo to their existing therapy. Open-label use of antihyperglycemic therapy was encouraged as required, aimed at reaching individually appropriate glycemic targets in all patients. To determine whether sitagliptin was noninferior to placebo, we used a relative risk of 1.3 as the marginal upper boundary. The primary cardiovascular outcome was a composite of cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for unstable angina. RESULTS: During a median follow-up of 3.0 years, there was a small difference in glycated hemoglobin levels (least-squares mean difference for sitagliptin vs. placebo, -0.29 percentage points; 95% confidence interval [CI], -0.32 to -0.27). Overall, the primary outcome occurred in 839 patients in the sitagliptin group (11.4%; 4.06 per 100 person-years) and 851 patients in the placebo group (11.6%; 4.17 per 100 person-years). Sitagliptin was noninferior to placebo for the primary composite cardiovascular outcome (hazard ratio, 0.98; 95% CI, 0.88 to 1.09; P<0.001). Rates of hospitalization for heart failure did not differ between the two groups (hazard ratio, 1.00; 95% CI, 0.83 to 1.20; P = 0.98). There were no significant between-group differences in rates of acute pancreatitis (P = 0.07) or pancreatic cancer (P = 0.32). CONCLUSIONS: Among patients with type 2 diabetes and established cardiovascular disease, adding sitagliptin to usual care did not appear to increase the risk of major adverse cardiovascular events, hospitalization for heart failure, or other adverse events

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p&lt;0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (&lt;1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (&lt;1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline